Active Ingredient(s):Ponatinib FDA Approved: * December 14, 2012 Pharm Company: *ARIAD PHARMACEUTICALS Category:Cancer
Ponatinib (trade name Iclusig /aklus/ eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion